Improvement in Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment - Case Report

被引:1
|
作者
Sachdev, Arun [1 ]
机构
[1] Macclesfield Hosp, Macclesfield, England
关键词
Case report; Photobiomodulation; Central serous chorioretinopathy; DIABETIC MACULAR EDEMA; THERAPY;
D O I
10.1007/s40123-024-00963-6
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Introduction: Central serous chorioretinopathy (CSCR) is a condition where fluid build-up accumulates underneath the retina, resulting in retinal pigment epithelium (RPE) detachment and vision loss. Irreversible retinal functional and anatomical changes are possible consequences. Research into novel strategies to aid in recovery are of interest. Photobiomodulation (PBM) uses light wavelengths to improve cellular function and shows positive effects in several conditions including those with edema. Methods: This prospective case report details a 39-year-old woman with CSCR. Multiwavelength PBM treatment was initiated with the Valeda (R) Light Delivery System. A series of treatment included nine sessions delivered over 3-5 weeks. Follow-up treatments were conducted. Optical coherence tomography (OCT) imaging and best-corrected visual acuity (BCVA) measures were taken. The patient has been followed for approximately 1 year. Results The patient presented with blurred vision and a BCVA score of 65 letters in the left eye. After 3 weeks of observation, the patient's vision had further declined two lines on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart to 55 letters. Fluorescein angiography was performed, confirming CSCR diagnosis, and PBM was initiated. PBM treatment improved BCVA and fluid build-up in the RPE within 1 week of treatment (three treatment sessions). Following the full series of treatment (nine PBM treatment sessions), fluid was completely resolved and BCVA scored at 80 letters. The patient had a repeat PBM treatment series similar to 6 months later and has shown stable vision and no fluid present on OCT scan. The patient was seen again similar to 1 year later with continued stable vision and no fluid detection. Conclusions PBM is a non-invasive treatment option that may provide benefit in CSCR to resolve fluid build-up, macular change, and vision loss. Research into PBM as an immediate treatment option for CSCR, especially those with chronic presentations or those posed to have irreversible damage, is warranted to confirm effectiveness.
引用
收藏
页码:2055 / 2060
页数:6
相关论文
共 50 条
  • [1] Improvement in Central Serous Chorioretinopathy in Renal Transplant Recipients Following Hemodialysis: Case Report
    Zeng, Zhuoran
    Zhang, Yonghong
    TRANSPLANTATION PROCEEDINGS, 2024, 56 (09) : 2058 - 2062
  • [2] A patient misdiagnosed with central serous chorioretinopathy: A case report
    Wang, Tian-Yu
    Wan, Zhong-Qi
    Peng, Qing
    WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (16) : 2341 - 2345
  • [3] A patient misdiagnosed with central serous chorioretinopathy: A case report
    Tian-Yu Wang
    Zhong-Qi Wan
    Qing Peng
    World Journal of Clinical Cases, 2019, (16) : 2341 - 2345
  • [5] Central serous chorioretinopathy: Treatment
    Park, Jong
    Kim, Kiyoung
    Kang, Min
    Kim, Eung
    Yu, Seung-Young
    TAIWAN JOURNAL OF OPHTHALMOLOGY, 2022, 12 (04) : 394 - 408
  • [6] A Case of Central Serous Chorioretinopathy after Tadalafil Treatment
    Yoon, Yo Sep
    Lee, Seunghwan
    Woo, Je Moon
    Min, Jung Kee
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2018, 59 (01): : 93 - 97
  • [7] Central Serous Chorioretinopathy Development following Cessation of Terbinafine Treatment
    Shmueli, Or
    Nitzan, Itay
    Averbukh, Edward
    CASE REPORTS IN OPHTHALMOLOGY, 2022, 13 (03): : 793 - 797
  • [8] Choroidal neovascularization following laser treatment of central serous chorioretinopathy
    Simon, P
    Glacet-Bernard, A
    Binaghi, M
    Coscas, G
    Soubrane, G
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2001, 24 (01): : 64 - 68
  • [9] Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone – a case report
    Ramesh Venkatesh
    Arpitha Pereira
    Kushagra Jain
    Naresh Kumar Yadav
    BMC Ophthalmology, 20
  • [10] Case Report: Erdafitinib-induced Central Serous Chorioretinopathy
    Claiborne, Richard T.
    Tsan, Grace L.
    OPTOMETRY AND VISION SCIENCE, 2022, 99 (01) : 88 - 92